Real-world results of first-line ABVD in patients with classic Hodgkin's lymphoma at a neoplastic disease institute in Lima, Peru.
Objective: To evaluate the clinical characteristics and outcomes of first-line ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) in patients with classical Hodgkin lymphoma treated at a neoplastic disease institute in Lima, Peru. Methods: Retrospective study of previously untreated classical H...
| Published in: | Revista Medica Herediana Vol. 36; no. 4; pp. 332 - 345 |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | research tables/charts Journal Article |
| Published: |
Universidad Peruana Cayetano Heredia
Oct-Dec2025
|
| Online Access: | View this record in EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=190640091&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 190640091 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 1018130X 25M1 jtl: Revista Medica Herediana issn: 1018130X maglogo: N pubinfo: dt: Oct-Dec2025 vid: 36 iid: 4 pid: 28405 pub: Universidad Peruana Cayetano Heredia artinfo: ui: 190640091 190640091 190640091 10.20453/rmh.v36i4.6535 190640091 ppf: 332 ppct: 13 formats: fmt: @attributes: type: P db: lth ui: 190640091 tig: atl: Real-world results of first-line ABVD in patients with classic Hodgkin's lymphoma at a neoplastic disease institute in Lima, Peru. aug: au: Salinas Agramonte, Luis Valencia Laurel, Grethel Alcarraz, Cindy Mantilla, Raúl Quintana, Shirley Vásquez, Jule Rioja, Patricia Bendezú, Elmer Motta Guerrero, Rodrigo Vidaurre, Tatiana affil: Departamento de Medicina Oncológica. Instituto Nacional de Enfermedades Neoplásicas. Lima, Perú sug: subj: Hodgkin's Disease Drug Therapy Doxorubicin Therapeutic Use Bleomycins Therapeutic Use Vinblastine Therapeutic Use Dacarbazine Therapeutic Use Treatment Outcomes Human Peru Male Female Adult Middle Age Retrospective Design Record Review Nonexperimental Studies Descriptive Statistics Cox Proportional Hazards Model Prospective Studies Confidence Intervals Data Analysis Software Progression-Free Survival Overall Survival Neoplasm Staging Neutropenia Nausea Drug Combinations Adult: 19-44 years Middle Aged: 45-64 years Male Female ab: Objective: To evaluate the clinical characteristics and outcomes of first-line ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) in patients with classical Hodgkin lymphoma treated at a neoplastic disease institute in Lima, Peru. Methods: Retrospective study of previously untreated classical Hodgkin lymphoma diagnosed between 2014 and 2018. All received ABVD days 1 and 15 every 28 days. We described clinical features, objective response rate (ORR), overall survival (OS), and adverse events (AEs) per CTCAE v5.0, and explored associations between clinical variables and response using the chi-square test. Results: A total of 157 patients were included, with a median age of 31.5 years (interquartile range [IQR]: 22-49.25), of whom 56.7% were male. The most common histological type was nodular sclerosis (64.3%). Bulky disease was present in 17.8%, mediastinal mass in 45.2%, and B symptoms in 76.4%. Disease stages were distributed as follows: stage I (5.1%), stage II (36.9%), stage III (34.4%), and stage IV (22.9%). The complete response (CR) rate was 97.1%. Over the 36 months, overall survival (OS) was 83.1%. Regarding toxicity, grade 3-4 neutropenia occurred in 31.8%, while the most frequent non-hematological toxicity was nausea (24.8%). Conclusions: In this cohort, first-line ABVD showed effectiveness with a toxicity profile comparable to prior reports, supporting its use in resource-limited settings. Optimizing supportive care and incorporating PET/ CT may help refine treatment selection and follow-up. Objetivo: Evaluar las características clínicas y los resultados del tratamiento de primera línea con ABVD (doxorrubicina, bleomicina, vinblastina y dacarbazina) en pacientes con linfoma de Hodgkin clásico atendidos en un instituto de enfermedades neoplásicas en Lima, Perú. Material y métodos: Estudio retrospectivo de pacientes con linfoma de Hodgkin clásico no tratados previamente, diagnosticados entre 2014 y 2018. Todos recibieron ABVD días 1 y 15 cada 28 días. Se describieron características clínicas, tasa de respuesta objetiva (TRO), supervivencia global (SG) y eventos adversos (EA) según CTCAE v5.0. Se exploraron asociaciones entre variables clínicas y respuesta mediante prueba de chi cuadrado. Resultados: Se incluyeron 157 pacientes con una mediana de edad de 31,5 años (rango intercuartílico [RIC]: 22-49,25), de los cuales el 56,7% eran varones. El tipo histológico más frecuente fue la esclerosis nodular (64,3%). El 17,8% presentaron enfermedad bulky, el 45,2% masa mediastinal y el 76,4% síntomas B. La distribución por estadios fue: estadio I (5,1%), estadio II (36,9%), estadio III (34,4%) y estadio IV (22,9%). La tasa de respuesta completa (RC) alcanzó el 97,1%. A los 36 meses, la supervivencia global (SG) fue del 83,1%. En cuanto a la toxicidad, la neutropenia de grado 3-4 se observó en el 31,8%, mientras que la toxicidad no hematológica más frecuente fueron las náuseas (24,8%). Conclusiones: En esta cohorte, el ABVD de primera línea mostró efectividad y un perfil de toxicidad seguro. La optimización del soporte y el empleo de PET/CT podrían contribuir a racionalizar mejor el tratamiento. pubtype: Academic Journal doctype: research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|